Johns Hopkins Medicine Johns Hopkins Logo
make a gift
hopkins urology on you tube  twitter urology department at hopkins   facebook urology department at hopkins  blog urology department at hopkins  
Robert Veltri, Ph.D. Robert Veltri, Ph.D.

Associate Professor of Urology
Johns Hopkins Medical Institutions


Dr. Veltri served on the faculty of microbiology and surgery of WVU from 1969-80, where his research covered the areas of infectious diseases, immunology, and cancer biomarkers. Dr. Veltri developed a fee for service clinical immunology and virology diagnostic testing service for the WVU hospital's department of clinical pathology that generated about $100,000 in revenue by 1980. Teaching responsibilities included medical, dental, nursing and graduate level students in areas of microbiology, virology, and cancer biology. He also trained and served as advisor for eight MS and seven Ph.D. graduate students of microbiology during his tenure at WVU. A total of seventeen Medical, Dental, and Medical Technology students did research clerkships in Dr. Veltri's laboratory during his tenure at WVU. He obtained more than $1.0 Million in extramural research funding while at WVU. Served as President of the WVU chapter of Sigma Xi and also received an outstanding teacher's award in 1976.

In 1981-84 Dr. Veltri established an R&D team, which developed the first diagnostic application for liposomes that consisted of rapid (1-2 minutes) and sensitive (10-fold improvement to ng/ml) slide co-agglutination diagnostic kits for infectious and rheumatologic diseases. Three Class II, FDA approved 510K products were transferred to manufacturing and released to market based upon a proprietary and patented co-agglutination technology that employed a proprietary method to prepare protein-A coated Liposomes and combine them with antibody coated latex particles. The three FDA approved tests were for Streptococcal Group A, Rheumatoid arthritis, and Infectious Mononucleosis.

In 1984, Dr. Veltri founded the American Biotechnology Company in Rockville, MD (acquired by Theracel Corporation in 1988). We discovered two unique classes of L-Ascorbic acid derivatives based upon the use of an Aldol and Michael addition series of modifications performed at the C-2 position of the molecule (see patents 1,2,4,5, 7 and 8 above). These small molecules were all of very low toxicity, water-soluble and demonstrated a variety of biological activities including anti-cancer, anti-infectious and anti-inflammatory activity.

In 1996, Dr. Veltri and his R&D team commercialized the first statistical-based (Logistic Regression model) and patented algorithm to predict prostate cancer post-operative stage based upon pre-treatment quantitative biopsy pathology as well as DNA ploidy and quantitative nuclear grade information determined by image analysis. The product was Trademarked “UroScoreTM”, a term suggested by Dr. Veltri. There are three publications (reference # 51, 77 and 88 in the above bibliography) on the subject.



B.A. 1961-63 Youngstown State University Biology/Chemistry
M.S. 1963-65 West Virginia University Microbiology
Ph.D. 1965-68 West Virginia University Microbiology


Positions Institutions Dates
Assistant Professor & Director of Research West Virginia University Medical School, Div. of Otolaryngology and Department of microbiology
Associate Professor & Director of Research West Virginia University Medical School, Div. of Otolaryngology and Department of microbiology
Professor & Director of Research West Virginia University Medical School, Div. of Otolaryngology and Department of microbiology
Director of virology and special immunology fee for service WVU hospital diagnostic laboratory West Virginia University Medical School and Department of Clinical Pathology
Director of R&D; Cooper- Biomedical, Inc., Malvern, PA
Project Director National Foundation for Cancer Research, Bethesda, MD
President/CEO American Biotechnology Company, Rockville, MD
Executive Vice President & Chief Scientific Officer Theracel, Inc., Rockville, MD
Vice President of R&D & Chief Scientific Officer CytoDiagnostics, Inc., OKC, OK.
Vice President of R&D and General Manager of R&D UroCor, Inc., OKC, OK.
Adjunct appointee in the department of pathology Oklahoma University Health Sciences Center, OKC, OK.
Institutional Biosafety Committee Oklahoma University Health Sciences Center, OKC, OK.
Governor of State of Oklahoma Health Research Committee member State of Oklahoma Center for Advancement of Science and Technology (OCAST)
Biotechnology Advisory Committee Oklahoma City Community College
Biomedical Engineering Advisory Board of the Department of Engineering University of Central Oklahoma
Technical supervisor of UroCor Clinical Chemistry laboratory UroCor, Inc.
Visiting Associate Professor Johns Hopkins University School of Medicine
Associate Professor Johns Hopkins University School of Medicine


   Free Access to abstracts at PubMed

  1. Veltri RW and BE Kirk. An antiviral substance in the tissues of mice acutely infected with lymphocytic choriomeningitis virus. J Gen Virol., 10(1):17-27, 1971.
  2. Veltri RW , Sprinkle PM, Keller SA, Chicklo JM. Immunoglobulin changes in a pediatric otolaryngic patient sample subsequent to T & A. J Laryngol Otol., 86(9):905-16, 1972.
  3. Veltri RW , Sprinkle PM, Keller SA, Chicklo JM. Ecological alterations of oral microflora subsequent to tonsillectomy and adenoidectomy. J Laryngol Otol., 86(9):893-903, 1972.
  4. Veltri RW and PM Sprinkle. Serous otitis media. Immunoglobulin and lysozyme levels in middle ear fluids and serum. Ann Otol Rhinol Laryngol., 82(3):297-301, 1973.
  5. Veltri RW , J.E. McClung and P.M. Sprinkle. Epstein-Barr Nuclear Antigens Carrying Lymphocytes in Human Palatine Tonsils. Journal of General Virology 32: 455-460, 1976.
  6. Veltri RW and P.M. Sprinkle. Secretory Otitis Media: An Immune Complex Disease Annals of Otology, Rhinology and Laryngology 85: (Supplement 25), 135-139, 1976.
  7. Sloyer JL, PM, Veltri RW and Sprinkle PM. In vitro IgM antibody synthesis by human tonsil-derived lymphocytes. J Immunol., 111(1):183-8. 1973.
  8. Sprinkle PM and Veltri RW . Quantitative alterations in the ecology of the oropharyngeal microflora subsequent to tonsillectomy and adenoidectomy. Trans Am Acad Ophthalmol. Otolaryngol., 78(2):ORL60-3, 1974.
  9. Sprinkle PM, Veltri RW and JE McClung. Epstein-Barr virus associated with episodes of recurrent tonsillitis. Arch Otolaryngol., 101(9):552-6, 1975.
  10. Sprinkle PM and Veltri RW . Secretory otitis media. An immune complex disease. Ann Otol Rhinol Laryngol., 85(2 Suppl 25 Pt 2):135-9, 1976.
  11. Veltri RW , W.H. Wainwright and P.M. Sprinkle. Immunological Identification of Epstein-Barr Virus Early Antigen in a P3HR-1 Cell Extract. Journal of the National Cancer Institute 57: 245-253, 1976.
  12. Sprinkle, P.M., Veltri RW and J.A. Wade. Clinical Significance of Viral Latency. The Laryngoscope, Vol. LXXXVI, No. 12: 1815-1823, 1976.
  13. Veltri RW , H.F. Mengoli, P.E. Maxim and S.S. Westfall. Isolation and Identification of Human Lung Tumor Associated Antigens. Cancer Research 37: 1313-1322, 1977.
  14. Maxim, P.E., Veltri RW and R.J. Pusateri. Chronic Serous Otitis Media: An Immune Complex Disease. Trans. Acad. Ophthalmology Otolaryngology 84: 234-238, 1977.
  15. Wainwright, W.H. and Veltri RW . Separation of the Complement Fixing and Early Antigens from Epstein-Barr Soluble Antigens. Journal of the National Cancer Institute 58: 111-1113, 1977.
  16. Sprinkle, P.M. and Veltri RW . The Tonsils and Adenoids. Clinical Otolaryngology 2: 153-167, 1977.
  17. Veltri RW , L.W. Heyl and P.M. Sprinkle. Epstein-Barr Virus Genome Carrying Lymphocyte Subpopulations of Human Palatine Tonsils. Proc. Soc. Exp. Biol. Med. 156: 282-286, 1977.
  18. Veltri RW , J.E. McClung and P.M. Sprinkle. Epstein-Barr Virus Antigens in Lymphocytes of Patients with Exudative Tonsillitis, Infectious Mononucleosis and Hodgkin’s Disease. Int. Journal of Cancer 21: 683-687, 1978.
  19. Maxim, P.E., Veltri RW , P.M. Sprinkle, R.J. Pusateri. Soluble Immune Complexes in Sera from Head and Neck Cancer Patients: A Preliminary Report: Trans Acad. Otolaryngol. 86: 428-432, 1978.
  20. Veltri RW , P.M. Sprinkle, P.E. Maxim, A.N. Theofilopoulos, S.M. Rodman, C.L. Kinney. An Immune Monitoring Protocol for Patients with Carcinoma of the Head and Neck: A Preliminary Report: Ann. Otology, Rhinology and Laryngology, Vol. 87(5), Pg. 692-700, 1978.
  21. Veltri RW , P.E. maxim, H.F. Mengoli and R.G. Burrell. Search for New Human Tumor Associated Antigens in Carcinoma of the Lung. 3rd International Symposium on Detection and Prevention of Cancer. Vol. II Pages 625-644, 1978.
  22. Mengoli, H.F., Veltri RW , C.W. Huang, P.E. Maxim and P.M. Sprinkle. Cationic Proteins of Normal Lung Tissue and Lung Carcinoma. 3rd International Symposium on Detection and Prevention of Cancer. Vol. II, Pages 625-655, 1977.
  23. Veltri RW , P.E. Maxim, P.M. Sprinkle, D.K. Flaherty and C. Kinney. Immunopathogenesis of Serous Otitis Media, pgs. 29-34. In: Proceedings of the Second National Conference on Otitis Media. R.J. Wiet and S.W.Coulthard eds., Ross Labs, Inc., Columbus 140: 22-32, 1979.
  24. Wainwright, W.H., Veltri RW , P.M. Sprinkle. Abrogation of Cell-Mediated Immunity by a Serum Blocking Factor (SBF) Isolated from Patients with Infectious Mononucleosis. J. Infectious Diseases 140: 22-32, 1979.
  25. Veltri RW , J.R. McKolanis, S.D. Rockoff and K.R. McIntire. Protein-A Antibody Binding (PAAB) Technique for Detection of Tumor Associated Membrane Antigen of Lewis Lung Carcinoma. Int. J. Cancer, 25 (1): 141-145, 1980.
  26. Veltri RW , Maxim, P.E. J.M. Boehlecke. Tumor-Associated Membrane Antigens (TAMA) Isolated from Human Squamous Cell carcinoma of the Lung. In Serologic Analysis of Human Cancer antigens, S. Rosenberg (Ed.) Academic Press Incorporated. New York, 1980.
  27. Maxim, P.E. and Veltri RW . Antigenic Mimicry Exhibited Between BCG and Human Neoplastic and Normal Tissue Extracts In: The Fifth Chicago Symposium on Cancer Immunology: Experimental and Clinical, Elsevier- North Holland, 1980.
  28. Veltri RW , Maxim, P.E., and J.M. Boehlecke. A Human tumor-Associated Membrane Antigen from Squamous-Cell Carcinoma of the Lung. Br. J. Cancer, 41: 705-715, 1980.
  29. Maxim, P.E., Veltri RW , and S. Westfall. Soluble Tumor Associated Markers in Lung Extracts. Oncology, 38: 147-153, 1981.
  30. Veltri RW , Wilson, W.R. and S. Sprinkle, P.M., Rodman, S.M. and D.A.Kavesh. Implication of Viruses in Idiopathic Sudden Hearing Loss: Primary Infection or Reactivation of Latent Viruses? American Academy of Otolaryngology, Oto H-N Surg. 89: 137-141, 1981.
  31. Veltri RW , Kikta, V.A., Wainwright, W.H. and P.M. Sprinkle. Biological and Molecular Characterization of the IgG-Serum Blocking Factor (SBF-IgG) Isolated from Sera of Patients with EBV-Induced Infectious Mononucleosis. Journal of Immunology 127 (1): 320-328, 1981.
  32. Veltri RW Raich, P.C., McClung, J.E., Shah, S.H. Sprinkle, P.M. Lymphomatoid Granulomatosis and Epstein - Barr virus. Cancer 50:1513-1517, 1982.
  33. Ockhizen, R., Pandey, J.P., Veltri RW , Arlen, M., Fudenberg, H. Hugh. Immunologlobulin Allotypes in Patients with Squamous Cell Carcinoma of the Head and Neck. Cancer 49(10): 2021-2024, 1982.
  34. Boyd, Edwin L., McClung, J.E., Veltri RW , Sprinkle P.M. Early Antigen Titers in Pediatric Patients with Acute Cervical Lymphadenitis. Otolaryngol. Head & Neck Surg. 90: 6-10, 1982.
  35. Grady, Dwight, McClung, J.E., Veltri RW , Sprinkle, P.M. and Veach, John S. Association of Epstein-Barr Virus with Acute Exudative Tonsillitis. Otolaryngol. Head & Neck Surg. 90: 11-15, 1982.
  36. Veltri RW and Sprinkle, P.M. Immune Responses in Non-Acute, Non-Purulent Otitis Media with Effusion. Proc. XIIth World Congress, Budapest, Hungary, 291-299, 1981.
  37. Veltri RW , Shah, S.H., McClung, J.E., Klingerberg, W.C. and Sprinkle, P.M. Epstein-Barr Virus, Fatal Infectious Mononucleosis and Hodgkin's Disease in Siblings. Cancer 51: 509-520, 1983.
  38. . McKolanis, J.R. and Veltri RW . Antibody Response to a Solubilized Tumor Associated Membrane Antigen (TAMA) from the Murine Lewis lung Tumor. Cancer Immunology and Immunotherapy 15: 131-137, 1983.
  39. Wilson, W.R., Veltri RW , Laird , N., and Sprinkle, P.M. Viral and Epidemiologic Studies of Idiopathic Sudden Hearing Loss. Otolaryngol. Head and Neck Surgery 91: 653-658, 1983.
  40. Dowler, K.W. and Veltri RW . In Vitro Neutralization of HSV-2: Inhibition by Binding of Normal IgG and Purified Fc to Virion Fc Receptor (FcR). Journal of Medical Virology 13: 251-259, 1984.
  41. Veltri RW and P.M. Sprinkle. Immunology of Otitis Media, Chapter 7, In: Immunobiology of the Head and Neck, Eds. J.F. Poliquin, A.F. Ryan, HJ.P. Harris. College-Hill Press, San Diego, CA. pp. 137-156, 1984.
  42. Veltri RW and P.E. Maxim. Tumor Immunity and Tumor Markers in Head and Neck Cancer. In: Cancer Treatment and Research, Head and Neck Oncology. Ed. G.T. Wolf, Martin Nijhoff Publishers, Boston, MA. pp. 411-430, 1984.
  43. Kung, V.T., P.E. Maxim, Veltri RW , and F.J. Martin. Antibody-Bearing Liposomes Improve Agglutination of Latex Particles used in Clinical Diagnostic Assays. Biochimica et. Biophysica Acta 839: 105-109, 1985.
  44. Veltri RW Immune Regulation in Carcinoma of the Head and Neck. In: Head and Neck Cancer, Vol. 1: 564-567, (Chretien/Johns/Shedd/Strong/Word eds.), B.C. Decker Inc., Philadelphia, PA., 1985.
  45. Veltri RW , G. Fodor, C.M. Liu, C.J. Woolverton, M.W. Baseler. A New Class of Synthetic Biological Response Modifiers: The Methylfurylbutyrolactones (NAFOCARE). J. Biol. Res. Mod. 5:444-461, 1986.
  46. Woolverton, C.J., Veltri RW , I.S. Snyder. Stimulation of Human PMN In Vitro by a Succinimide Molecular Complex of Methylfurylbutyrolactones. J. Biol. Res. Mod. 5(6):527-538, 1986.
  47. Maxim, P.E. and Veltri RW . Serum Ferritin as a Tumor Marker in Patients with Squamous Cell Carcinoma of the Head and Neck. Cancer 57:305-311, 1986.
  48. Veltri RW , S.M. Rodman, P.E. Maxim, M.W. Baseler and P.M. Sprinkle. Immune Complexes, Serum Proteins, Cell-Mediated Immunity and Immune Regulation in Patients with Squamous Cell Carcinoma of the Head and Neck. Cancer 57: 2295-2308, 1986.
  49. Baseler, M.W., P.E. Maxim, and Veltri RW . Circulating IgA Immune Complexes in Head and Neck Cancer, Nasopharyngeal Carcinoma, Lung Cancer, and Colon Cancer. Cancer 59: 1727-1731, 1987.
  50. Fodor, G.B., K. Sussangkarn, R. Arnold, H. Mathelier, T. Mohacsi, R. Mujumdar, J. Butterwick, and Veltri RW . From methyglyoxal to new immunopotentiating ascorbic acid derivatives. Acta Biochim. Biophys. Hung. 22(2-3): 165-179, 1987.
  51. Veltri RW , Alan W. Partin, Jonathan I. Epstein, Garry M. Marley, M. Craig Miller, et al. Quantitative Nuclear Morphometry, Markovian Texture Descriptors, and DNA content Captured on a CAS-200 Image Analysis System, Combined with PCNA and Her-2/neu Immunohistochemistry for Prediction of Prostate Cancer Progression. J. Cellular Biochemistry, Suppl. 19: 249-258, 1994.
  52. Hu, Y., K. Ashenayi, Veltri RW , R. Hurst, and R. Bonner. Neural Network Based Bladder Cancer Cell Classification. Proceedings of World Congress on Neural Networks, San Diego. Volume 1: 416-21, 1994.
  53. Bostwick DG, Burke HB, Wheeler TM, Chung LW, Bookstein R, Pretlow TG, Nagle RB, Montironi R, Lieber MM, Veltri RW , et al. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J Cell Biochem Suppl, 19:283-289, 1994.
  54. Ostrander GK, Blair JB, Stark BA, Marley GM, Bales WD, Veltri RW , Hinton DE, Okihiro M, Ortego LS, Hawkins WE. Long-term primary culture of epithelial cells from rainbow trout Oncorhynchus mykiss) liver. In Vitro Cell Dev Biol Anim, May;31(5):367-78, 1995.
  55. Carmichael, M.J., Veltri RW , A.W. Partin, M. Craig Miller, P.C. Walsh, J.I. Epstein. Deoxyribonucleic Acid Ploidy Analysis as a Predictor of Recurrence Following Radical Prostatectomy for Stage T2 Disease. J. Urology 153: 1015-1019, 1995.
  56. Berges, RR, J Vukanovic, JI Epstein, M CarMichael, L Cisek, DE Johnson, Veltri RW , PC Walsh, and JT Isaacs. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1: 473-480, 1995.
  57. McCue PA, Gomella LG, Veltri RW , Marley GM, Miller MC, Lattime EC. Development of secondary structure, growth characteristics and cytogenetic analysis of human transitional cell carcinoma xenografts in scid/scid mice. J Urol, Mar;155(3):1128-32, 1996.
  58. An G, Luo G, Veltri RW , O'Hara SM. Sensitive, nonradioactive differential display method using chemiluminescent detection. Biotechniques, Mar;20(3):342-4, 346, 1996.
  59. Badalament, RA, M. Craig Miller, Paul A. Peller, Donn C. Young, Duke K. Bahn, Paul Kochie, Gerard J. O’Dowd, and Veltri RW . An Algorithm for Predicting Non-organ Confined Prostate Cancer Using the Results Obtained From Sextant Core Biopsies and Prostate Specific Antigen Level. J. Urology 156: 1375-80, 1996.
  60. Veltri RW , M. Craig Miller, Alan W. Partin, Donald S. Coffey, and Jonathan I. Epstein. Ability to Predict Biochemical Progression Using Gleason Score and Computer-Generated Quantitative Nuclear Grade Derived from Cancer Cell Nuclei. Urology 48: 685-91, 1996.
  61. Hurst Robert E, Johnny B. Roy, K.W. Kim, Veltri RW , Garry M. Marley, Kevin P. Patton, Dena L. Schackelford, Paul Stein, and C. Lowell Parsons. A Deficit of Chondroitin Sulfate Proteoglycans on Bladder Uroepithelium in Interstitial Cystitis. Urology 48: 817-821, 1996.
  62. Marley, G.M., M. Craig Miller, M. W. Kattan, Gang Zhao, K.P. Patton, R.L. Vessella, G.L. Wright Jr., P.F. Schellhammer, and Veltri RW . Free and Complexed Prostate Specific Antigen Serum Ratios to Predict Probability of Primary Prostate Cancer and Benign Prostatic Hyperplasia. Urology 48(6A): 16-22, 1996.
  63. Weinstein, MH, AW Partin, Veltri RW , and JI Epstein. Neuroendocrine Differentiation in Prostate cancer. Enhanced Prediction of Progression after Radical Prostatectomy. Human Pathology 27: 683-87, 1996.
  64. Moreno JG, O'Hara SM, Long JP, Veltri RW , Ning X, Alexander AA, Gomella LG. Transrectal ultrasound-guided biopsy causes hematogenous dissemination of prostate cells as determined by RT-PCR. Urology, Apr;49(4):515-20, 1997.
  65. Hurst RE, RB Bonner, K Ashenayi, Veltri RW , and GP Hemstreet, III. Neural Net-based identification of cells expressing the p300 tumor-related antigen using fluorescence image analysis. Cytometry 27: 36-42, 1997.
  66. Silberman, MA, AW Partin, Veltri RW , and JI Epstein. Tumor Angiogenesis Correlates with Progression after Radical Prostatectomy but Not with Pathologic Stage in Gleason Sum 5 to 7 Adenocarcinoma of the prostate. Cancer 79:772-79, 1997.
  67. Slaton, JW, CPN Dinney, Veltri RW , MC Miller, M Leibert, GJ O’Dowd, and HB Grossman. DNA Ploidy enhances the cytologic prediction of Recurrent Transitional Cell Carcinoma of the Bladder. J. Urology, 158: 806-811, 1997.
  68. O’Dowd, GJ. Veltri RW , R. Orozco, M. Craig Miller, JP Osterling. Update on the Appropriate Staging Evaluation for Newly Diagnosed Prostate Cancer. J. Urology 158: 687-698, 1997
  69. Orozco, R. GJ O’Dowd, B. Kunnel, M. Craig Miller, Veltri RW , Observations of Pathology Trends in 62,537 Prostate Biopsies Obtained from Urology Private Practices in the United States. Urology, 51: 186-195, 1998.
  70. Veltri RW , GO O’Dowd, R. Orozco, M. Craig Miller, The Role of Biopsy Pathology, Quantitative Nuclear Morphometry, and Biomarkers in the Pre-operative Prediction of Prostate Cancer Staging and Prognosis. Seminars in Urologic Oncology, 16(3): 106-107, 1998.
  71. Wojcik, EM, M. Craig Miller, GJ O’Dowd, Veltri RW , The Value of Computer Assisted Quantitative Nuclear Grading in Differentiation of Normal Urothelial Cells from Low and High Grade Transitional Cell Carcinomas. Analytical and Quantitative Cytology and Histology, 20: 69-76, 1998.
  72. Wojcik, EM, M. Craig Miller, BC Wright, Veltri RW , GJ O’Dowd. Comparative Analysis of DNA Content in Polyoma virus-Infected Urothelial Cells, Urothelial Dysplasia and High Grade Transitional Cell Carcinoma. Analytical and Quantitative Cytology and Histology, 19: 430-436, 1997.
  73. Veltri RW , Miller MC, Zhao G, Ng AY, Marley GM, Wright GL, Vessella RL, and Ralph DA. Interleukin-8 (IL-8) serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 53: 139-47, 1999.
  74. An G, Cazares L, Luo G, Miller MC, Wright GL, and Veltri RW . Differential expression of full length and a truncated Her-2/neu oncogene receptor in prostate cancer assessed using relative quantitative RT-PCR. Mol Urol 2: 305-310, 1999.
  75. Veltri RW and Miller MC. Free/Total PSA Ratios improve differentiation of benign and malignant disease of the prostate: Critical Analysis of two different test populations. Urology 53(4): 736-45, 1999.
  76. Ng A, Bales WD, and Veltri RW . Phenylbutyrate induced apoptosis and differential expression of BCL-2, BAX, p53, and FAS in human Prostate Cancer Cell Lines. Analytical and Quantitative Cytology and Histology 22(1): 45-54, 2000.
  77. An G, Meka RCS, Bright SP, and Veltri RW . Human prostate specific transglutaminase (pTGase) gene: Promoter cloning, tissue specific expression and down regulation in metastatic prostate cancer (CaP). Urology 54: 1105-1111, 1999.
  78. Potter, SR, Miller MC, Mangold LA, Jones KA, Epstein JI, Veltri RW and Partin AW. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology 54: 791-795, 1999.
  79. Reckwitz T, Potter SR, Snow PB, Zhang Z, Veltri RW , and Partin AW. Artificial neural networks in urology: Update 2000. Prostate Cancer & Prostatic Diseases 2: 222-226, 1999.
  80. An Gang, AY Ng, CS Reddy Meka, G Luo, SO Bright, L Cazares, GL Wright, and Veltri RW . Cloning and characterization of UROC28, a novel gene overexpressed in prostate, breast and bladder cancers. Cancer Research 60: 7014-7020, 2000.
  81. O’Dowd, GJ, MC Miller, R Orozco, and Veltri RW . Analysis of repeat biopsy results within one year following a non-cancer diagnosis. Urology 55 (4):553-59, 2000.
  82. Marks LS, Partin AW, Epstein JI, Tyler VE, Simon I, Macairan ML, Chan TL, Dorey FJ, Garris JB, Veltri RW , Santos PBC, Stonebrook KA, and DeKernion JB. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 163(5): 1451-1456, 2000.
  83. Veltri RW , Miller MC, and An G. Standardization, analytical validation, and quality control of intermediate endpoint biomarkers. Urology 57(Suppl 4A), 164-70, 2001.
  84. Veltri RW , Partin, AW, and Miller, MC. Quantitative nuclear grade (QNG): A new image analysis-based biomarker of clinically relevant nuclear structure alterations. J. Cellular Biochemistry, 35: (Suppl), 151-157, 2000.
  85. Veltri RW , Miller MC, Partin, AW, Poole Ed, and O’Dowd GJ. Prediction of prostate cancer stage using quantitative biopsy pathology. Cancer 91: 2322-2328, 2001.
  86. Prescott JL, Montie J, Pugh TW, McHugh T, and Veltri RW . Clinical sensitivity of p53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens. Cancer 91: 2127-2135, 2001.
  87. Miller MC, O’Dowd GJ, Partin AW, and Veltri RW . Contemporary use of complexed PSA and calculated Free PSA for Early Detection of Prostate Cancer: Impact of Changing Disease Demographics. Urology 57: 1105-1111, 2001.
  88. Veltri RW , Miller MC, Mangold LA, O'Dowd GJ, Epstein JI, Partin AW. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge. J Urol 168(1):100-4, 2002.
  89. An G and Veltri RW . Differential display polymerase chain reaction using chemiluminescent detection. In: Luminescence Biotechnology. Eds. Knox Van Dyke, Christopher Van Dyke, and Karen Woodfork. CRC Press (Boca Raton, New York, and Washington, DC), 2002.
  90. Veltri RW , Ph.D., M. Craig Miller. B.S., Gerard J. O’Dowd. M.D., and Alan W. Partin, M.D., Ph.D. Impact of Age on Total and Complexed PSA Cutoffs in a Contemporary Referral Series of Men with Prostate Cancer. Urology 60 (Suppl 4A): 47-52, 2002.
  91. Sawczuk IS, Cynthia L. Pickens, Usha R. Vasa, David A. Ralph , Ph.D., Kathy A. Norris, M. Craig Miller, B.S., Angela Y. Ng, H. Barton Grossman, and Veltri RW . DD23 Biomarker: A Prospective Clinical Assessment In Routine Urinary Cytology Specimens From Patients Being Monitored For TCC. Urologic Oncology 7: 185-190, 2002.
  92. GIlbert SM, A Shabsigh, Sawczuk A, U Vasa, Angela Ng, C Pickens, K Norris, S Bright, GJ O’Dowd, MC Benson, CA Olsson, AS Sawczuk and Veltri RW ,. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma (TCC) of the bladder in patients with a history of bladder cancer. Urology 61: 539-543, 2003.
  93. Veltri RW , Leonard S. Marks, M. Craig Miller, Wes D. Bales, John Fan, Maria Luz MaCairan, Jonathan I. Epstein, and Alan W. Partin. Saw Palmetto Alters Nuclear Measurements Reflecting DNA Content In Men With Symptomatic BPH: Evidence For A Possible Molecular Mechanism. Urology 60: 617-22, 2002.
  94. Veltri, Robert W. , Manisha Chaudhari , M Craig Miller , Edward C. Poole, Gerard J. O’Dowd and Alan W. Partin. Comparison of Logistic Regression and Neural Net Modeling for Prediction of Prostate Cancer Pathologic Stage. Clin Chem. 48(10): 1828-34, 2002.
  95. Ellison LE, Cheli C, Bright S, Veltri RW , and Partin AW. Cost-benefit analysis of total PSA, Free/Total PSA and complexed PSA for prostate cancer screening. Urology 60 (Suppl 4A): 42-46, 2002.
  96. Haese A, Chaudhari M, Miller MC, Epstein JI, Graefen M, Hammerer P, Palisaar J, Huland H, Poole EC, O’Dowd GJ, Partin AW, and Veltri RW . Quantitative biopsy pathology for the prediction of pathologically organ confined prostate cancer: A multiinstitutional validation study. Cancer 97: 969-78, 2003.
  97. Presti JC, O’Dowd GJ, Miller MC, Mattu R, and Veltri RW . Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in PSA and age-related cancer rates – results of a community multipractice study. J Urology 169: 125-129, 2003.
  98. Gretzer MB, Alan W Partin, Daniel W Chan, and Veltri RW . Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization (SELDI). Reviews in Urology, June, 2003.
  99. Khan MA, Alan W. Partin, Harry G. Rittenhouse, Stephen D. Mikolajczyk, Lori J. Sokoll, Daniel W. Chan, and Veltri RW . Evaluation of Pro-PSA for the Early Detection of Prostate Cancer in Men with a total PSA Range of 4.0-10 ng/ml. J Urology 170: 723-726, 2003.
  100. Khan MA, H. Ballentine Carter, Jonathan I. Epstein, Michael C. Miller, Patricia Landis, Patrick C. Walsh, Alan W. Partin and Veltri RW . Can PSA derivatives and pathological parameters predict significant change in expectant management criteria for men with prostate cancer? J Urology 170: 2274-78, 2003.
  101. Khan MA, Patrick C. Walsh, Michael C. Miller, Wesley D. Bales, Jonathan I. Epstein, Leslie A. Mangold, Alan W. Partin and Veltri RW . Quantitative alterations in nuclear structure predict prostate cancer distant metastasis and death in men with biochemical recurrence post-radical prostatectomy. Cancer, 98: 2583-9, 2003.
  102. Park Jae, Lori J. Sokoll, Debra J. Bruzek, Leslie Mangold, Robin Gurganus, Masood A. Khan, Alan W. Partin, Daniel W. Chan, and Veltri RW . Comparison of total PSA and derivative levels in a screening population of African-American, Caucasian, and Korean-American men. Clinical Prostate Cancer, 2: 173-76, 2004.
  103. Veltri RW , Khan MA, Miller MC, Epstein JI, Mangold LA, Walsh PC, Partin AW. Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate. Clin Cancer Res., 10(10): 3465-73, 2004.
  104. Veltri RW , Alan W. Partin, and M. Craig Miller. Quantitative Nuclear Grade (QNG): The clinical applications of the quantitative measurement of nuclear structure using image analysis. In: Cancer Drug Discovery and Development. Gary J. Kelloff, Ernest T. Hawk and Caroline C. Sigman, Eds. The Humana Press Inc., Totowa, NJ, 2004. (In Press).
  105. Gretzer MB, Daniel W Chan, C. L. van Rootselaar, J.M. Rosenzweig, S. Dalrymple, L.A. Mangold, Alan W Partin, and Veltri RW . Proteomic analysis of Dunning Prostate Cancer Cell Lines with Variable Metastatic Potential using SELDI-TOF. Prostate. 60:(4):325-31, 2004.
  106. Veltri, RW, Jae Park, M.C. Miller, Leonard S. Marks, Munekado Kojima, Cameron van Rootselaar, Masood A. Khan, and Alan W. Partin. Stromal-Epithelial Measurements of Prostate Cancer in Native Japanese and Japanese-American Men. Prostate Cancer Prostatic Dis. 7(3):232-7, 2004.

  107. Marks LS, Kojima M, Demarzo A, Heber D, Bostwick DG, Qian J, Dorey FJ, Veltri RW, Mohler JL, Partin AW. Prostate cancer in native Japanese and Japanese-American men: Effects of dietary differences on prostatic tissue. Urology, 64(4):765-71, 2004.

  108. Rogers CG, MA Khan, MC Miller, RW Veltri, and AW Partin. Natural history of progression in patients who fail to achieve an undetectable PSA following radical prostatectomy. Cancer, 2004;101:2549–56.

  109. Bast RC, Jr., Hans Lilja, N Urban, DL Rimm, H Fritsche, J Gray, R Veltri, G Klee, A Allen, N Kim, S Gutman, M.A. Rubin11 and A Hruszkewycz. Translational Crossroads for Biomarkers. Clin. Cancer Res. (In Press) 2005.





    American Academy of Microbiology




    Society for Basic Research in Urology (SBUR)


1976 WVU School of Medicine outstanding teacher award
1979 Elected a Fellow of the American Academy of Ophthalmology and Otolaryngology
Visiting professor of microbiology at the University of Chile in Santiago from July 28-August 8, 1981. I was one of three faculty that taught a course in viral oncogenesis and tumor immunology. My portion of the course consisted of eleven lectures, two seminars, and three laboratory sessions. Also, the faculty made me an honorary member of the Chilean Society of Microbiology.
1975-76 President of the WVU Chapter of Sigma Xi, a research honorary. Initiated a interdisciplinary research competition in science for graduate students in the sciences.
Certificate of Recognition from Governor Keating for his services in helping to advance science and technology in Oklahoma presented by Dr. William A Sibley, President of Oklahoma Center for the Advancement of Science and Technology (OCAST) on October 30, 2001. Also a letter of appreciation was included from Dr. Kathy Kocan on behalf of the Health Research Committee.


  1. Szent-Gyorgyi A, Fodor G, Veltri RW. 2-Furylbutyrolactone derivatives, their preparation, compositions containing them, and their use for modulation of the immune system in mammals. Patent No. 4,518,611; Issued: May 21,1985. Assigned to Theracel Corp., Rockville , MD.
  2. Veltri RW, Maxim PE, Fodor G. 2-Furylbutyrolactone modulation of the immune system in mammals. Patent No. 4,518,611 issued 05-21-85. Assigned to Theracel Corp., Rockville, MD.
  3. Maxim PE and Veltri RW. Assaying for circulating immune complexes with labeled protein A. Patent No. 4,617,262, Issued October 14, 1986. Assigned to CooperBiomedical Inc., Palo Alto, CA.
  4. Veltri, RW and Maxim PE. Method of treating inflammation in mammals utilizing ketobutyrolactones and furylbutyrolactones. Patent No. 4,883,813, Issued November 28, 1989. Assigned to Theracel Corp., Rockville, MD.
  5. Fodor G, Sussangkarn K. and Veltri RW. Condensation products of cyclic diketones and ascorbic acid as immunomodulatory agents. Patent No. 4,883,808 issued 11-28-89. Assigned to Theracel Corp., Rockville, MD.
  6. Fox, SW and Veltri RW. Microencapsulated antitumor agent. Patent No. 4,963,364, Issued October 16, 1990. Assigned to the inventors.
  7. Veltri RW, Fodor G, and Sussangkarn K. Pharmaceutically useful furyl substituted dihydroxyethylbutyrolactones. Patent No. 5,102,909 issued 04-07-92. Assigned to Theracel Corp., Rockville, MD.
  8. Veltri RW and Fodor G. Pharmaceutically useful Michael addition products of unsaturated aldehydes and ketones and ascorbic acid. Patent No. 5,098,933 issued 03-24-92. Assigned to Theracel Corp., Rockville, MD.
  9. An G, O’Hara SM, Ralph DA and Veltri RW. Biomarkers and targets for diagnosis, prognosis and management of prostate disease. Patent No. 5,882,864 issued 03-16-1999. Assigned to UroCor, Inc., Oklahoma City, OK.
  10. Gang An and Robert W. Veltri Biomarkers and targets for diagnosis, prognosis and management of prostate diseases. Patent No. 5,972,615. Issued October 26, 1999. Assigned to UroCor, Inc., Oklahoma City, OK.
  11. Gang An, Veltri RW et al Biomarkers and targets for diagnosis, prognosis and management of prostate, breast, and bladder cancer. Patent Number 6,218,529 issued on 4/1/2001., Assigned to UroCor, Inc., Oklahoma City, OK.
  12. Garry M. Marley and R.W. Veltri. Method for Selectively Inducing Biomarker Expression in Urologic Tumor Tissue for Diagnosis and Treatment Thereof. Patent No. 5,856,112 issued 01-5-1999. Assigned to UroCor, Inc., Oklahoma City, OK.
  13. Veltri RW, Miller MC, Bacus MP, Ashenayi K. A sextant core biopsy predictive mechanism for non-organ-confined disease status”. Issued November 23, 1999. Patent No. 5,989,811, issued 09-29-2000. Assigned to UroCor, Inc., Oklahoma City, OK.
  14. Robert W. Veltri, Michael P. Bacus, M. Craig Miller. Prediction of Prostate Cancer Progression by Analysis of Selected Biomarkers. Patent No. 6,025 128, issued 02-15-2000. Assigned to UroCor, Inc., Oklahoma City, OK.
  15. Gang An and RW Veltri. A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer. Patent No. 6,156,515 Issued December 5, 2000. Assigned to UroCor.
  16. Ralph DA, An G, and Veltri RW. Diagnosis of disease state using mRNA profiles in peripheral leukocytes. Patent No. 6,190,857 issued February 20, 2001. Assigned to UroCor, Inc., Oklahoma City, OK.
  17. An, Gang and Veltri, Robert. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer. Patent No. 6,369,195 issued April 9, 2002. Assigned to UroCor, Inc., Oklahoma City, OK.
  18. Veltri, Robert W., Ashenayi, Kaveh, Hu, Ying and O'Dowd, Gerard J. Neural network for cell image analysis for identification of abnormal cells. Patent No. 6,463,438 issued October 8, 2002. Assigned to UroCor, Inc., Oklahoma City, OK.
  19. Veltri RW. Trademark, “UroScoreTM”. Serial No. 7468233 registered January 16, 1996 to UroCor Inc., Oklahoma City, OK. Registration No. 1948820 for Laboratory research services in the field of oncology.
  20. Veltri RW. Trademark, Quantitative Nuclear Grade “QNGTM”. Serial No. 76173213 registered March 19, 2002 to UroCor Inc. of Oklahoma City, OK. Registration No. 2549632 for Medical services for detecting, staging, and prognosis of cancer.




  • Address:
    The Brady Urological Research Institute, Room 409, 600 North Wolfe Street , Baltimore, MD 21287
  • Appointments: (410) 955-6380
  • Fax: (410) 614-3695

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: | 600 North Wolfe Street, Baltimore, Maryland 21287